Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. - Wikidata - wikimedia - TriplyDB

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

http://www.wikidata.org/entity/Q33571321

about

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism Regulation and function of the FGF23/klotho endocrine pathways Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease Fibroblast Growth Factor-23-A Potential Uremic Toxin Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis The use of fibroblast growth factor 23 testing in patients with kidney disease.The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort.Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss.Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency.The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.Update on fibroblast growth factor 23 in chronic kidney disease.Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.Fibroblast growth factor 23 and bone mineralisation.Phosphate Toxicity in CKD: The Killer among Us Fibroblast growth factor-23: what we know, what we don't know, and what we need to know.Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5/6 nephrectomized rats.A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease.Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review Disorders of phosphorus homeostasis.Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?Cinacalcet: will it play a role in reducing cardiovascular events?The role of FGF23 in CKD--with or without Klotho.The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications.Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new.Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.The effect of vitamin D status on risk factors for cardiovascular disease.FGF-23 and secondary hyperparathyroidism in chronic kidney disease.Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.Emerging drugs for secondary hyperparathyroidism.

P2860

Q24187385-22235C33-4ED9-4D08-9A9E-89AE5C2849BA Q26852624-C5045463-371B-4B5A-9CE5-70E40E5B9272 Q26860470-50C6773F-AEA9-40AB-979D-DC0A8A1B2133 Q27000415-CEEA728A-14D3-45CE-8F74-89424CAA7B71 Q27024043-9F66DC51-1192-49C1-BC63-10BA8E4051DC Q28075648-0AF34101-7D5E-41F8-8D48-1B00B1A8401D Q28484646-E8A044F7-ED4E-428B-BCDD-C198EE012BE8 Q33835743-0CB4B3C7-EDCD-4D9F-9802-3B01E67378AA Q34027561-194175C6-8A2A-4C60-8800-D407491A863C Q34244300-597CAEEB-9926-4152-B99F-67CB3E0A0A28 Q34281434-A37A708E-67A1-45AC-A466-9665A583B68C Q34385273-37D2D5C5-C71B-4A6F-AA79-8A260AEBAE12 Q34718202-7DA4AC50-76EB-4BB3-A4CE-5CF179602FC9 Q34739121-0BDA621B-A8E5-4B1B-B2EF-37768C6A74FE Q35468992-EEE3388C-922D-42DA-AC4B-B5116511254F Q35682152-9D23E5EF-C290-428F-B06F-EAEA48D71595 Q35735678-185054BA-30DF-4A8C-AA0A-3EC4BB5B11F3 Q35914820-CA4013A3-1D96-4EA3-B93D-1724399E3020 Q35920190-6ED3BAC6-7FC6-4041-B9BB-82F162D72338 Q35967107-782E6BFC-8C9F-4151-9CB2-A704B581429C Q36210285-9603B10E-7123-40E6-87A4-C7BA1997B55F Q36225208-A8A4F896-3988-4665-90DA-A020CD03FB39 Q36756061-8A648B4C-EBBD-4703-9E84-37C7F6A782A1 Q36965142-695635C8-26A1-402A-A666-7C6B87B91428 Q37162723-16AD05EA-6EB7-4411-8EB0-25981046ADEB Q37328071-CB34BA75-FC89-4C9E-B20F-4CAC9F7307B0 Q37365294-3F69A19F-F17B-4D85-B91D-394E3845E04C Q37695914-B913FFE2-0FBA-4F41-9C3D-4B9A8B62B6E0 Q37801814-595174C4-44FA-4526-9C7B-307C30AF3850 Q37832285-6DE262CC-7384-4C33-919F-D2511456726E Q37891153-8CB036DC-5B39-49E7-AF6A-379CBF3FBB8C Q37993874-D5277692-DD7E-4CBD-A722-902283235E57 Q38020094-08BD4F2F-6948-49B2-9738-F4BA61024627 Q38053246-EE721F28-354D-4C28-8AD9-F4256235A6F9 Q38072533-43BD9FFB-25E7-4D2E-94CE-0F12C1AD6AA8 Q38079128-47177433-A6D0-4DCD-B23D-18D794C0D85A Q38100985-FFF9D3C0-8E11-42EB-899F-F9B952AF46AB Q38123396-F52DFDCC-42EF-4729-9C78-039968FB8851 Q38141236-D3145F2E-9798-4BFF-9938-53B47FEF9A2F Q38363615-B405AD2D-A95B-4FCA-BCAF-819921DBA056

P2860

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

http://www.wikidata.org/entity/Q33571321

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

@ast

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

@en

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

@nl

type

label

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

@ast

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

@en

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

@nl

prefLabel

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

@ast

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

@en

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

@nl

P1433

Q33571321-806958CD-1347-4E5E-B673-B9D8B7D19828

P1476

Q33571321-B45B9114-365F-427B-AFFC-D7ABF840745D

P2093

Q33571321-74562C41-8786-4898-93E5-3C3BB07FD85C

Q33571321-9DBF060E-9712-402D-BDD8-87CC3177DB27

Q33571321-ADAC8DD9-74C8-47FF-A5D0-E9DC43D517B8

Q33571321-E767AEF2-72E4-4E13-BE06-956115102DE2

P2860

Q33571321-02C5D06A-56EB-467B-8C05-36A7D7811C14

Q33571321-11FB7FD2-618F-4092-8E21-71E5F1FDA315

Q33571321-1B9AF7E3-A9C5-4371-871F-B34FE6FA16A2

Q33571321-1E491E62-E0E5-4273-B59F-54B19D55FE89

Q33571321-25F76583-D987-401B-A2D0-50ADBE6C0CFE

Q33571321-305E8E85-5B42-4C6B-BC81-F869A8071ECA

Q33571321-35B4CCFD-5A21-45B5-86E6-789DC461D31B

Q33571321-47826AC8-3034-4C25-A3CB-F8450B0427A1

Q33571321-57A212A7-FE9B-43AB-9B00-91351B1A3E17

Q33571321-5F5E3135-F22F-46AA-BC0B-1E5686C7ED98

P304

Q33571321-FC29704D-E3C4-444A-80BE-5E2D926C3F4D

P31

Q33571321-BED30F44-32A6-4177-B4B6-64591E85B634

P356

Q33571321-BDA65A41-F138-4964-9C12-2CE5E5BCC7FC

P433

Q33571321-AB606E0D-224B-4D5C-A06E-69B152151ED6

P478

Q33571321-6DAC371E-D3C1-4023-BFF7-C705FB4124D8

P50

Q33571321-16932E32-0764-4812-BE28-2EADC2901028

P577

Q33571321-7DFF4AD4-6E7B-45BC-A4E2-2312F93C1A00

P698

Q33571321-B1DCBC45-E20E-4380-A230-CEF00305CA42

P921

Q33571321-17434BB6-4EFA-496B-86E7-E8F4E61CA0BF

Q33571321-d8bdd945-d1cd-4806-960d-de4bd4bd789f

P932

Q33571321-7C9D7D36-6075-4DB9-B81A-AF8BDEB882CB

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD

@en

P2093

James B Wetmore

http://www.w3.org/2001/XMLSchema#string

Rochelle Menard

http://www.w3.org/2001/XMLSchema#string

Ron Krebill

http://www.w3.org/2001/XMLSchema#string

Shiguang Liu

http://www.w3.org/2001/XMLSchema#string

P2860

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain

Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway

Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production

Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro

The parathyroid is a target organ for FGF23 in rats

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

P304

110-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.03630509

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

L. Darryl Quarles

P577

2009-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19965548

http://www.w3.org/2001/XMLSchema#string

P921

P932

2801647

http://www.w3.org/2001/XMLSchema#string